Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

b.braun petzold gmbh 34212 melsungen nemecko -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

b.braun petzold gmbh 34212 melsungen nemecko -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

changzhou hualian health dressing co., ltd. no. 55 yuejin road 213144 zouqu town, changzhou Čína -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

changzhou hualian health dressing co., ltd. no. 55 yuejin road 213144 zouqu town, changzhou Čína -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

changzhou hualian health dressing co., ltd. no. 55 yuejin road 213144 zouqu town, changzhou Čína -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

changzhou hualian health dressing co., ltd. no. 55 yuejin road 213144 zouqu town, changzhou Čína -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

changzhou hualian health dressing co., ltd. no. 55 yuejin road 213144 zouqu town, changzhou Čína -

Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bsn medical gmbh quickbornstrasse 24 20253 hamburg nemecko -

Európai Unió - szlovák - EMA (European Medicines Agency)

laboratoires delbert - histamín dihydrochloride - leukémia, myeloidná, akútna - immunostimulants, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). Účinnosť lieku ceplene nebola úplne preukázaná u pacientov starších ako 60 rokov.

Európai Unió - szlovák - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pozri časti 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.